CN1447688A - 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法 - Google Patents

使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法 Download PDF

Info

Publication number
CN1447688A
CN1447688A CN01814168A CN01814168A CN1447688A CN 1447688 A CN1447688 A CN 1447688A CN 01814168 A CN01814168 A CN 01814168A CN 01814168 A CN01814168 A CN 01814168A CN 1447688 A CN1447688 A CN 1447688A
Authority
CN
China
Prior art keywords
substituted
cancer
angiogenesis
branched chain
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01814168A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·卡平
D·P·宾加曼
D·A·格玛施
G·格拉夫
J·M·亚妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1447688A publication Critical patent/CN1447688A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01814168A 2000-08-14 2001-08-13 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法 Pending CN1447688A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513300P 2000-08-14 2000-08-14
US60/225,133 2000-08-14

Publications (1)

Publication Number Publication Date
CN1447688A true CN1447688A (zh) 2003-10-08

Family

ID=22843668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01814168A Pending CN1447688A (zh) 2000-08-14 2001-08-13 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法

Country Status (18)

Country Link
US (1) US20020037929A1 (https=)
EP (1) EP1309323B1 (https=)
JP (2) JP5586117B2 (https=)
KR (1) KR20030017653A (https=)
CN (1) CN1447688A (https=)
AR (1) AR030345A1 (https=)
AT (1) ATE345123T1 (https=)
AU (2) AU2001283337B2 (https=)
BR (1) BR0113204A (https=)
CA (1) CA2417282C (https=)
DE (1) DE60124560T2 (https=)
DK (1) DK1309323T3 (https=)
ES (1) ES2275710T3 (https=)
MX (1) MXPA03001057A (https=)
PL (1) PL366220A1 (https=)
PT (1) PT1309323E (https=)
WO (1) WO2002013804A2 (https=)
ZA (1) ZA200300782B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309747A (pt) * 2002-05-03 2005-04-26 Alcon Inc Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
PT1586316E (pt) 2003-01-21 2008-05-28 Senju Pharma Co Preparação líquida aquosa contendo ácido 2-amino-3-(4- bromobenzoil)fenilacético
US7879905B2 (en) * 2004-11-09 2011-02-01 Alcon, Inc. 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
US20100292289A1 (en) * 2007-11-30 2010-11-18 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with novel amides
RU2010138799A (ru) * 2008-02-21 2012-03-27 Иста Фармасьютикалз (Us) Офтальмологические нестероидные противовоспалительные средства в качестве адъювантов
US8962686B2 (en) * 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
WO2001035181A1 (en) * 1999-11-11 2001-05-17 Wireless Methods Ltd. Remote switching and actuation of electrical devices

Also Published As

Publication number Publication date
DK1309323T3 (da) 2007-03-19
JP5586117B2 (ja) 2014-09-10
DE60124560D1 (de) 2006-12-28
AU2001283337B2 (en) 2006-06-15
ES2275710T3 (es) 2007-06-16
WO2002013804A3 (en) 2002-06-06
CA2417282A1 (en) 2002-02-21
EP1309323B1 (en) 2006-11-15
PL366220A1 (en) 2005-01-24
KR20030017653A (ko) 2003-03-03
AU8333701A (en) 2002-02-25
HK1057331A1 (en) 2004-04-02
WO2002013804A2 (en) 2002-02-21
AR030345A1 (es) 2003-08-20
BR0113204A (pt) 2006-02-21
EP1309323A2 (en) 2003-05-14
ATE345123T1 (de) 2006-12-15
JP2004520267A (ja) 2004-07-08
JP2012193214A (ja) 2012-10-11
DE60124560T2 (de) 2007-09-06
ZA200300782B (en) 2004-08-27
PT1309323E (pt) 2007-01-31
MXPA03001057A (es) 2004-09-10
CA2417282C (en) 2009-12-22
US20020037929A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
JP2012193214A (ja) ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法
CN1088992C (zh) 治疗眼炎的含3－苯甲酰基苯乙酸衍生物的局部给药组合物
CN1711087A (zh) 用于治疗眼新生血管性或水肿性紊乱和疾病的组蛋白脱乙酰酶抑制剂
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
JP2018537507A (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
EP1309322B1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
AU2001283337A1 (en) Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid
US6646003B2 (en) Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
JP2003160485A (ja) 消炎鎮痛点眼剤
JP2004506010A5 (https=)
CN1649575A (zh) 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法
CN1085528C (zh) 炎痛静在治疗由tnf引起的病理疾病中的用途
US20040132773A1 (en) Method of treating neurodgenerative disorders of the retina and optic nerve head
AU2001281258B2 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
US20030187072A1 (en) Method of treating angiogenesis-related disorders
HK1057331B (en) Treatment of angiogenesis-related disorders using benzoyl phenylacetic acid derivatives
HK1057332B (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
AU2001281258A1 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
AU2006217547A1 (en) Method of treating angiogenesis-related disorders
JPH0797318A (ja) オキシフェドリンを必須成分とする眼圧降下剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication